[1] | Banerji J, Rusconi S, Schaffner W . Expression of a beta- globin gene is enhanced by remote SV40 DNA sequences. Cell, 1981,27(2 Pt 1):299-308. [DOI] | [2] | Blackwood EM, Kadonaga JT . Going the distance: a current view of enhancer action. Science, 1998,281(5373):60-63. [DOI] | [3] | Bulger M, Groudine M . Functional and mechanistic diversity of distal transcription enhancers. Cell, 2011,144(3):327-339. [DOI] | [4] | Sun CB, Zhang X . Advance in the research on super- enhancer. Hereditas(Beijing), 2016,38(12):1056-1068. | [4] | 孙长斌, 张曦 . 超级增强子研究进展. 遗传, 2016,38(12):1056-1068. [DOI] | [5] | Levine M . Transcriptional enhancers in animal development and evolution. Curr Biol, 2010,20(17):R754-763. [DOI] | [6] | Sengupta S, George RE . Super-enhancer-driven transcriptional dependencies in cancer. Trends Cancer, 2017,3(4):269-281. [DOI] | [7] | Ing-Simmons E, Seitan VC, Faure AJ, Flicek P, Carroll T, Dekker J, Fisher AG, Lenhard B, Merkenschlager M . Spatial enhancer clustering and regulation of enhancer- proximal genes by cohesin. Genome Res, 2015,25(4):504-513. [DOI] | [8] | Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA . Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell, 2013,153(2):307-319. [DOI] | [9] | Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, Hoke HA, Young RA . Super-enhancers in the control of cell identity and disease. Cell, 2013,155(4):934-947. [DOI] | [10] | Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA, Bradner JE, George RE, Gray NS, Young RA, Wong KK . Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell, 2014,26(6):909-922. [DOI] | [11] | Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham BJ, Lee TI, Bradner JE, Young RA . Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol Cell, 2015,58(2):362-370. [DOI] | [12] | Saint-André V, Federation AJ, Lin CY, Abraham BJ, Reddy J, Lee TI, Bradner JE, Young RA . Models of human core transcriptional regulatory circuitries. Genome Res, 2016,26(3):385-396. [DOI] | [13] | Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, Faquin WC, Queimado L, Qi J, Wick MJ, El-Naggar AK, Bradner JE, Moskaluk CA, Aster JC, Knoechel B, Bernstein BE . An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat Genet, 2016,48(3):265-272. [DOI] | [14] | Adam RC, Fuchs E . The Yin and Yang of chromatin dynamics in stem cell fate selection. Trends Genet, 2016,32(2):89-100. [DOI] | [15] | Kaufman CK, Mosimann C, Fan ZP, Yang S, Thomas AJ, Ablain J, Tan JL, Fogley RD, van Rooijen E, Hagedorn EJ, Ciarlo C, White RM, Matos DA, Puller AC, Santoriello C, Liao EC, Young RA, Zon LI . A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science, 2016, 351(6272): aad2197. [DOI] | [16] | Witte S, Bradley A, Enright AJ, Muljo SA . High-density P300 enhancers control cell state transitions. BMC Genomics, 2015,16:903. [DOI] | [17] | Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA . Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell, 2013,153(2):320-334. [DOI] | [18] | Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE . Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell, 2013,24(6):777-790. [DOI] | [19] | Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo-Martin M, Llobet-Navás D, Cordon-Cardo C, Clappier E, Soulier J, Ferrando AA . A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat Med, 2014,20(10):1130-1137. [DOI] | [20] | Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, Loh ML, Hunger SP, Sanda T, Young RA, Look AT . Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science, 2014,346(6215):1373-1377. [DOI] | [21] | Sengupta D, Kannan A, Kern M, Moreno MA, Vural E, Stack B, J r., Suen JY, Tackett AJ, Gao L . Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. Epigenetics, 2015,10(6):460-466. [DOI] | [22] | Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH, Caruso BT, Arefolov A, Fadeyi O, Christie AL, Du K, Banka D, Schneider EV, Jestel A, Zou G, Si C, Ebmeier CC, Bronson RT, Krivtsov AV, Myers AG, Kohl NE, Kung AL, Armstrong SA, Lemieux ME, Taatjes DJ, Shair MD . Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature, 2015,526(7572):273-276. [DOI] | [23] | Johnatty SE, Tyrer JP, Kar S, Beesley J, Lu Y, Gao B, Fasching PA, Hein A, Ekici AB, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Rossing MA, Doherty JA, Chang-Claude J, Modugno F, Ness RB, Moysich KB, Levine DA, Kiemeney LA, Massuger LF, Gronwald J, Lubinski J, Jakubowska A, Cybulski C, Brinton L, Lissowska J, Wentzensen N, Song H, Rhenius V, Campbell I, Eccles D, Sieh W, Whittemore AS, McGuire V, Rothstein JH, Sutphen R, Anton-Culver H, Ziogas A, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Pearce CL, Pike MC, Stram DO, Wu AH, Kupryjanczyk J, Dansonka- Mieszkowska A, Rzepecka IK, Spiewankiewicz B, Goodman MT, Wilkens LR, Carney ME, Thompson PJ, Heitz F, du Bois A, Schwaab I, Harter P, Pisterer J, Hillemanns P, Group AGOS, Karlan BY, Walsh C, Lester J, Orsulic S, Winham SJ, Earp M, Larson MC, Fogarty ZC, Hogdall E, Jensen A, Kjaer SK, Fridley BL, Cunningham JM, Vierkant RA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Bandera EV, Orlow I, Pejovic T, Bean Y, Hogdall C, Lundvall L, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Sellers T, Kennedy C, Chiew YE, Berchuck A, MacGregor S, Pharoah PD, Goode EL, deFazio A, Webb PM, Chenevix-Trench G , Australian Ovarian Cancer Study G. Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the ovarian cancer association consortium. Clin Cancer Res, 2015,21(23):5264-5276. [DOI] | [24] | Zhang X, Choi PS, Francis JM, Imielinski M, Watanabe H, Cherniack AD, Meyerson M . Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet, 2016,48(2):176-182. [DOI] | [25] | Yang H, Schramek D, Adam RC, Keyes BE, Wang P, Zheng D, Fuchs E . ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas. eLife, 2015,4:e10870. [DOI] | [26] | Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ . CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell, 2015,163(1):174-186. [DOI] | [27] | Jiang YY, Lin DC, Mayakonda A, Hazawa M, Ding LW, Chien WW, Xu L, Chen Y, Xiao JF, Senapedis W, Baloglu E, Kanojia D, Shang L, Xu X, Yang H, Tyner JW, Wang MR, Koeffler HP . Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut, 2017,66(8):1358-1368. [DOI] | [28] | Togel L, Nightingale R, Chueh AC, Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D, Dhillon AS, Dawson MA, Diez-Dacal B, Gahman TC, Filippakopoulos P, Shiau AK, Mariadason JM . Dual targeting of bromodomain and extraterminal domain proteins, and WNT or MAPK signaling, inhibits c-MYC expression and proliferation of colorectal cancer cells. Mol Cancer Ther, 2016,15(6):1217-1226. [DOI] | [29] | Hanahan D, Weinberg RA . The hallmarks of cancer. Cell, 2000, 100(1):57-70. [DOI] | [30] | Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell, 2011,144(5):646-674. [DOI] | [31] | Suzuki HI, Young RA, Sharp PA . Super-enhancer- mediated RNA processing revealed by integrative microRNA network analysis. Cell, 2017,168(6):1000-1014 e15. [DOI] | [32] | Xie JJ, Jiang YY, Jiang Y, Li CQ, Chee LM, An O, Mayakonda A, Ding LW, Long L, Sun C, Lin LH, Chen L, Wu JY, Wu ZY, Cao Q, Fang WK, Yang W, Meltzer SJ, Yang H, Fullwood M, Xu LY, Li EM, Lin DC, Koeffler HP . Super-enhancer-driven long non-coding RNA LINC01503, regulated by TP63, is over-expressedand oncogenic in squamous cell carcinoma. Gastroenterology, 2018, 154(8): 2137- 2151.e1. [DOI] | [33] | Jiao W, Chen Y, Song H, Li D, Mei H, Yang F, Fang E, Wang X, Huang K, Zheng L, Tong Q . HPSE enhancer RNA promotes cancer progression through driving chromatin looping and regulating hnRNPU/p300/EGR1/HPSE axis. Oncogene, 2018,37(20):2728-2745. [DOI] | [34] | Cheng X, Yang Q, Tan ZD, Tan Y, Pu H, Zhao X, Zhang SH, Zhu L . The current research status of enhancer RNAs. Hereditas(Beijing), 2017,39(9):784-797. | [34] | 程霄, 杨琼, 谭镇东, 谭娅, 蒲红州, 赵雪, 张顺华, 朱砺 . 增强子RNA研究现状. 遗传, 2017,39(9):784-797. [DOI] | [35] | Lin CY, Erkek S, Tong Y, Yin L, Federation AJ, Zapatka M, Haldipur P, Kawauchi D, Risch T, Warnatz HJ, Worst BC, Ju B, Orr BA, Zeid R, Polaski DR, Segura-Wang M, Waszak SM, Jones DT, Kool M, Hovestadt V, Buchhalter I, Sieber L, Johann P, Chavez L, Groschel S, Ryzhova M, Korshunov A, Chen W, Chizhikov VV, Millen KJ, Amstislavskiy V, Lehrach H, Yaspo ML, Eils R, Lichter P, Korbel JO, Pfister SM, Bradner JE, Northcott PA . Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature, 2016,530(7588):57-62. [DOI] | [36] | Oldridge DA, Wood AC, Weichert-Leahey N, Crimmins I, Sussman R, Winter C, McDaniel LD, Diamond M, Hart LS, Zhu S, Durbin AD, Abraham BJ, Anders L, Tian L, Zhang S, Wei JS, Khan J, Bramlett K, Rahman N, Capasso M, Iolascon A, Gerhard DS, Guidry Auvil JM, Young RA, Hakonarson H,Diskin SJ, Look AT, Maris JM . Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature, 2015,528(7582):418-421. [DOI] | [37] | Super-enhancers facilitate gene regulation by signaling pathways. Cancer Discov, 2015, 5(5): OF11. [DOI] | [38] | Nabet B, P óB, Reyes JM, Shieh K, Lin CY, Will CM, Popovic R, Ezponda T, Bradner JE, Golden AA, Licht JD . Deregulation of the ras-erk signaling axis modulates the enhancer landscape. Cell Rep, 2015,12(8):1300-1313. [DOI] | [39] | Adelman K, Lis JT . Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. Nat Rev Genet, 2012,13(10):720-731. [DOI] | [40] | Galli GG, Carrara M, Yuan WC, Valdes-Quezada C, Gurung B, Pepe-Mooney B, Zhang T, Geeven G, Gray NS, de Laat W, Calogero RA, Camargo FD . YAP drives growth by controlling transcriptional pause release from dynamic enhancers. Mol Cell, 2015,60(2):328-337. [DOI] | [41] | Yimlamai D, Fowl BH, Camargo FD . Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol, 2015,63(6):1491-1501. [DOI] | [42] | Wang H, Zang C, Taing L, Arnett KL, Wong YJ, Pear WS, Blacklow SC, Liu XS, Aster JC . NOTCH1-RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. Proc Natl Acad Sci USA, 2014,111(2):705-710. [DOI] | [43] | Sur I, Taipale J . The role of enhancers in cancer. Nat Rev Cancer, 2016,16(8):483-493. [DOI] | [44] | Vaharautio A, Taipale J . Cancer. Cancer by super-enhancer. Science, 2014,346(6215):1291-1292. [DOI] | [45] | Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA . Transcriptional amplification in tumor cells with elevated c-Myc. Cell, 2012,151(1):56-67. [DOI] | [46] | Didiasova M, Schaefer L, Wygrecka M . Targeting GLI transcription factors in cancer. Molecules, 2018,23(5):1003. [DOI] | [47] | Nilson KA, Guo J, Turek ME, Brogie JE, Delaney E, Luse DS, Price DH . THZ1 reveals roles for Cdk7 in co-transcriptional capping and pausing. Mol Cell, 2015,59(4):576-587. [DOI] | [48] | Di Micco R, Fontanals-Cirera B, Low V, Ntziachristos P, Yuen SK, Lovell CD, Dolgalev I, Yonekubo Y, Zhang G, Rusinova E, Gerona-Navarro G, Canamero M, Ohlmeyer M, Aifantis I, Zhou MM, Tsirigos A, Hernando E . Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. Cell Rep, 2014,9(1):234-247. [DOI] | [49] | Bartkowiak B, Liu P, Phatnani HP, Fuda NJ, Cooper JJ, Price DH, Adelman K, Lis JT, Greenleaf AL . CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev, 2010,24(20):2303-2316. [DOI] | [50] | Liang K, Gao X, Gilmore JM, Florens L, Washburn MP, Smith E, Shilatifard A . Characterization of human cyclin- dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Mol Cell Biol, 2015,35(6):928-938. [DOI] | [51] | Shin HY . Targeting super-enhancers for disease treatment and diagnosis. Mol Cells, 2018,41(6):506-514. [DOI] | [52] | Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S . Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res, 2017,77(9):2476-2487. [DOI] | [53] | Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, Kahatt C, Raffoux E, Stathis A, Thieblemont C, Quesnel B, Cunningham D, Riveiro ME, Rezai K . Phase I population pharmacokinetic assessment of the oral bromodomain inhibitor OTX015 in patients with haematologic malignancies. Clinical Pharmacokinetics, 2016,3(55):397-405. [DOI] | [54] | Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H . Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose- escalation, phase 1 study. The Lancet Haematology, 2016,3(4):186-195. [DOI] | [55] | Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, Perez-Atayde A, Wong KK, Yuan GC, Gray NS, Young RA, George RE . CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN- driven cancer. Cell, 2014,159(5):1126-1139. [DOI] | [56] | Wong RWJ, Ngoc PCT, Leong WZ, Yam AWY, Zhang T, Asamitsu K, Iida S, Okamoto T, Ueda R, Gray NS, Ishida T, Sanda T . Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. Blood, 2017,130(21):2326-2338. [DOI] | [57] | Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM, Manz T, Hao M, Bartkowiak B, Greenleaf AL, Marto JA, Geyer M, Bullock AN, Young RA, Gray NS . Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol, 2016,12(10):876-884. [DOI] | [58] | Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, Weir BA, Tsherniak A, Parasuraman S, Kim S, Alexe G, Stegmaier K . Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget, 2015,6(30):30178-30193. [DOI] | [59] | Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell, 2011,146(6):904-917. [DOI] | [60] | Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE . Selective inhibition of BET bromodomains. Nature, 2010,468(7327):1067-1073. [DOI] | [61] | Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, Herait P, Kahatt C, Lokiec F, Salles G, Facon T, Palumbo A, Cunningham D, Zucca E, Thieblemont C . Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol, 2016,3(4):e196-204. [DOI] | [62] | Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE. DRUG DEVELOPMENT . Phthalimide conjugation as a strategy for in vivo target protein degradation. Science, 2015,348(6241):1376-1381. [DOI] | [63] | Tasdemir N, Banito A, Roe JS, Alonso-Curbelo D, Camiolo M, Tschaharganeh DF, Huang CH, Aksoy O, Bolden JE, Chen CC, Fennell M, Thapar V, Chicas A, Vakoc CR, Lowe SW . BRD4 connects enhancer remodeling to senescence immune surveillance. Cancer Discov, 2016,6(6):612-629. [DOI] | [64] | Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, Kim ND, Look T, Mitsiades CS, Weng AP, Brown JR, Benes CH, Marto JA, Young RA, Gray NS . Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 2014,511(7511):616-620. [DOI] |
|